ES2174573T3 - Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas. - Google Patents

Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas.

Info

Publication number
ES2174573T3
ES2174573T3 ES99308129T ES99308129T ES2174573T3 ES 2174573 T3 ES2174573 T3 ES 2174573T3 ES 99308129 T ES99308129 T ES 99308129T ES 99308129 T ES99308129 T ES 99308129T ES 2174573 T3 ES2174573 T3 ES 2174573T3
Authority
ES
Spain
Prior art keywords
compound
activity
determining
pde
cox
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99308129T
Other languages
English (en)
Inventor
Li Liu
Bing Zhu
Li Han
Joseph W Thompson
Rifat Pamukeu
Gary A Piazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Pathways Inc
Original Assignee
Cell Pathways Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/173,375 external-priority patent/US6200771B1/en
Priority claimed from US09/366,003 external-priority patent/US6130053A/en
Priority claimed from US09/414,628 external-priority patent/US20020009764A1/en
Application filed by Cell Pathways Inc filed Critical Cell Pathways Inc
Application granted granted Critical
Publication of ES2174573T3 publication Critical patent/ES2174573T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se da a conocer una composición farmacéutica para el tratamiento de la neoplasia, que comprende un portador farmacéuticamente aceptable y un compuesto seleccionado por: determinación de la actividad inhibitoria de la ciclooxigenasa (COX) del compuesto; determinación de la actividad de inhibición del PDE del compuesto en el que el PDE se caracteriza por: (a) especificidad del cGMP sobre cAMP; (b) comportamiento cinético cooperativo en presencia de sustrato de cGMP; (c) afinidad submicromolecular por cGMP; y (d) insensibilidad a la incubación con quinasa de proteína dependiente de cGMP; y selección del compuesto que tiene actividad inhibitoria de COX inferior que dicha actividad de PDE para tratamiento de la neoplasia. La invención también provee un procedimiento para seleccionar el tratamiento de la neoplasia, que comprende determinación de la actividad inhibitoria de la ciclooxigenasa (COX) del compuesto; determinación de la actividad inhibitoria de PDE2 del compuesto; y selección del compuesto con actividad inhibitoria del COX inferior para el tratamiento de la neoplasia.
ES99308129T 1998-10-15 1999-10-14 Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas. Expired - Lifetime ES2174573T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/173,375 US6200771B1 (en) 1998-10-15 1998-10-15 Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US09/366,003 US6130053A (en) 1999-08-03 1999-08-03 Method for selecting compounds for inhibition of neoplastic lesions
US09/414,628 US20020009764A1 (en) 1999-10-08 1999-10-08 Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds

Publications (1)

Publication Number Publication Date
ES2174573T3 true ES2174573T3 (es) 2002-11-01

Family

ID=27390268

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99308129T Expired - Lifetime ES2174573T3 (es) 1998-10-15 1999-10-14 Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas.

Country Status (13)

Country Link
EP (2) EP1161943A3 (es)
JP (1) JP2000186047A (es)
CN (1) CN100389829C (es)
AT (1) ATE214920T1 (es)
AU (1) AU770308B2 (es)
CA (1) CA2284853A1 (es)
DE (1) DE69901082T2 (es)
DK (1) DK0997145T3 (es)
ES (1) ES2174573T3 (es)
IL (1) IL132366A0 (es)
NO (2) NO994995L (es)
TR (1) TR199902578A3 (es)
TW (1) TWI239837B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1133689A4 (en) * 1998-11-25 2002-10-30 Cell Pathways Inc METHOD FOR DIAGNOSTICING NEOPLASIA
US6569638B1 (en) * 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
KR100821446B1 (ko) * 2000-08-21 2008-04-10 아스트라제네카 아베 퀴나졸린 유도체
WO2004044234A1 (en) * 2002-11-13 2004-05-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with human phosphodiesterase 2a (pde2a)
DE60336934D1 (de) 2003-10-03 2011-06-09 Veijlen N V Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten
WO2005054181A1 (ja) * 2003-12-01 2005-06-16 Reverse Proteomics Research Institute Co., Ltd. 抗癌剤の新規標的タンパク質および対応する新規抗癌剤（スプナール）
JP5219135B2 (ja) * 2008-07-25 2013-06-26 独立行政法人産業技術総合研究所 炎症性疾患モデル動物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650720B2 (en) * 1991-03-08 1994-06-30 Fgn, Inc. Method for treating patients with precancerous lesions by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
US6063818A (en) * 1996-06-13 2000-05-16 Cell Pathways Inc. Substituted benzylidene indenyl formamides, acetamides and propionamides
US5998477A (en) * 1996-06-13 1999-12-07 Cell Pathways Inc. Substituted methoxy benzylidene indenyl-acetic and propionic acids for treating patients with precancerous lesions
DK0957903T3 (da) * 1996-09-18 2005-11-21 Applied Genetics Inc Dermatics Norbornen- og norbornandiolforbindelser til behandling af pigmenteringslidelser, neurodegenerative sygdomme eller proliferative hudlidelser
CA2238283C (en) * 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
EP1044187B1 (en) * 1997-12-12 2004-01-02 OSI Pharmaceuticals, Inc. N-benzyl-3-indenylacetamides derivatives for treating neoplasia

Also Published As

Publication number Publication date
TR199902578A2 (xx) 2000-06-21
AU770308B2 (en) 2004-02-19
DE69901082D1 (de) 2002-05-02
DK0997145T3 (da) 2002-07-29
EP0997145B1 (en) 2002-03-27
EP1161943A2 (en) 2001-12-12
CN1255379A (zh) 2000-06-07
JP2000186047A (ja) 2000-07-04
ATE214920T1 (de) 2002-04-15
NO994995D0 (no) 1999-10-14
IL132366A0 (en) 2001-03-19
CA2284853A1 (en) 2000-04-15
EP1161943A3 (en) 2003-12-10
NO994995L (no) 2000-04-17
TR199902578A3 (tr) 2000-06-21
TWI239837B (en) 2005-09-21
NO20062682L (no) 2000-04-17
AU5401099A (en) 2000-04-20
DE69901082T2 (de) 2002-08-29
CN100389829C (zh) 2008-05-28
EP0997145A1 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
BR0316502A (pt) Compostos quìmicos
NO941937L (no) Sakarinderivater som inhiberer proteolytiske enzymer
BR0013966A (pt) Compostos espiroeterocìclicos úteis como inibidores reversìveis de proteases de cisteìna
FI925787A0 (fi) Proteolytiska enzymers sackarinderivatinhibitorer
BR0012243A (pt) Triflúor butenos nematocidas
ES2282685T3 (es) Derivados de hidroxietilamina para el tratamiento de la enfermedad de alzheimer.
EA200200208A1 (ru) Синергитическая композиция
MD1507G2 (ro) Inhibitori, compoziţie farmaceutică pe baza lor şi procedeu de inhibare a HIV proteazei
MA27933A1 (fr) Inhibiteurs de l'activite de akt
BR9813508A (pt) Inibição de replicação viral associada com membrana
BG105112A (bg) Средство с антидепресивно действие
CO4790154A1 (es) Compuestos heterociclicos como inhibidores de enzimas rota- masas
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
GB0222514D0 (en) Organic compounds
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2174573T3 (es) Procedimientos de identificacion de substancias para la inhibicion de las lesiones neoplasticas.
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
ATE298246T1 (de) Aktiviertes protein c zur behandlung von pankreatitis
AR025379A1 (es) 9a-azalidas con actividad antibacteriana.
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
AR024963A1 (es) Oxazincarbazoles en el tratamiento de enfermedades del snc

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 997145

Country of ref document: ES